SCHEMBL3329013

SCHEMBL3329013

CCOc1ccc(-c2c(C#N)c(N)nc(SCc3cccc(NS(C)(=O)=O)c3)c2C#N)cc1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 18/20 0.79
ADORA2B P29275 6/20 0.58
ADORA3 P0DMS8 2/20 0.57
ADORA2A P29274 3/20 0.56
KDM4E B2RXH2 2/20 0.56
ALDH1A1 P00352 2/20 0.56
NPSR1 Q6W5P4 2/20 0.56
HSD17B10 Q99714 2/20 0.56
HPGD P15428 1/20 0.56
MEN1 O00255 1/20 0.53
POLB P06746 1/20 0.53
MAPT P10636 1/20 0.53
TSHR P16473 1/20 0.53
PPARG P37231 1/20 0.53
SMAD3 P84022 1/20 0.53
KMT2A Q03164 1/20 0.53
NCOA2 Q15596 1/20 0.53
NCOA1 Q15788 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
RXFP1 Q9HBX9 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3327818 0.92 ADORA1 (0.76) ADORA1ADORA2BKDM4EALDH1A1HSD17B10
SCHEMBL3363232 0.89 ADORA1 (0.85) ADORA1ADORA2BADORA3ADORA2AKDM4E
SCHEMBL3343650 0.88 ADORA1 (1.00) ADORA1ADORA2BADORA2AKDM4EALDH1A1
SCHEMBL3345477 0.85 ADORA1 (1.00) ADORA1ADORA2BADORA2AKDM4EALDH1A1
SCHEMBL10148609 0.82 ADORA1 (0.61) ADORA1ADORA2BADORA2AKDM4EALDH1A1
SCHEMBL3346799 0.77 ADORA1 (1.00) ADORA1ADORA2BADORA3
SCHEMBL10148810 0.76 ADORA1 (0.65) ADORA1ADORA2BADORA3ADORA2AKDM4E
SCHEMBL15168829 0.76 ADORA1 (0.65) ADORA1ADORA2BADORA3ADORA2AKDM4E
SCHEMBL244063 0.75 ADORA1 (0.77) ADORA1ADORA2BADORA2AKDM4EALDH1A1
SCHEMBL8034134 0.75 ADORA1 (0.63) ADORA1ADORA2BADORA3ADORA2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160130230-A1 SUBSTITUTED DICYANOPYRIDINES AND USE THEREOF BAYER INTELLECTUAL PROPERTY GMBH (DE) 2016-05-12 US disclosed
US-9187428-B2 Substituted dicyanopyridines and use thereof BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-11-17 US disclosed
US-20130210795-A1 SUBSTITUTED DICYANOPYRIDINES AND USE THEREOF BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-08-15 US disclosed
WO-2012000945-A1 SUBSTITUTED DICYANOPYRIDINES AND USE THEREOF BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130210795-A1 SUBSTITUTED DICYANOPYRIDINES AND USE THEREOF QDPR, DPYD, DDC ADORA1 3010/4885ADORA2B 2447/4885ADORA3 2434/4885
US-20160130230-A1 SUBSTITUTED DICYANOPYRIDINES AND USE THEREOF QDPR, DPYD, DDC ADORA1 3010/4885ADORA2B 2447/4885ADORA3 2434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.